Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...
Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...
Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...
Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...
The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...
Number 5: A prospective cohort study found that switching back from the biosimilar SB2 to the reference infliximab did not affect clinical disease activity or safety in inflammatory bowel disease (IBD ...
Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback